Change search
ReferencesLink to record
Permanent link

Direct link
Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Paediatrics.
Department of Pediatrics, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark.
Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway.
GPP Practice, Dolny Kubin, Slovakia.
Show others and affiliations
2009 (English)In: The Pediatric Infectious Disease Journal, ISSN 0891-3668, E-ISSN 1532-0987, Vol. 28, no 10, e276-282 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was determined following a simplified 2-dose priming and the more commonly employed 3-dose priming both followed by a booster dose. METHODS: A total of 351 healthy subjects were primed with PHiD-CV at either 3 and 5 or 3, 4 and 5 months of age followed in all subjects by a booster dose at 11 to 12 months of age. Serotype-specific pneumococcal responses were measured by 22F-inhibition ELISA and opsonophagocytic assays 1 month following primary and booster vaccinations. RESULTS: Depending on the serotype, the percentages of subjects reaching the ELISA antibody threshold of 0.2 microg/mL were 92.8% to 98.0% following 2 primary doses and 96.1% to 100% following 3 primary doses except for serotype 6B (55.7% and 63.1%, respectively) and serotype 23F (69.3% and 77.6%, respectively). Opsonophagocytic activity (OPA) could be measured in 74.4% to 100% and 88.9% to 100% of the subjects after the 2-dose or 3-dose priming, respectively, except for serotype 1 (60.8% and 62.9%, respectively). In both groups, robust increases in ELISA antibodies and OPA titers were observed for all serotypes after the booster dose. Higher postprimary and postbooster ELISA antibody levels and OPA titers were observed for most serotypes following the 3+1 schedule. CONCLUSION: PHiD-CV was immunogenic in both schedules, but further effectiveness data are needed to fully understand the public health benefit to be expected from these schedules in terms of prevention against invasive and mucosal infections.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2009. Vol. 28, no 10, e276-282 p.
Keyword [en]
pneumococcal conjugate 10-valent vaccine, immunogenicity, 2-dose primary schedule (2+1 schedule)
National Category
URN: urn:nbn:se:umu:diva-35063DOI: 10.1097/INF.0b013e3181b48ca3PubMedID: 20118683OAI: diva2:328546
Available from: 2010-07-05 Created: 2010-07-05 Last updated: 2011-12-06Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Silfverdal, Sven Arne
By organisation
In the same journal
The Pediatric Infectious Disease Journal

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 39 hits
ReferencesLink to record
Permanent link

Direct link